Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma

NCT00193258 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

94

Enrollment

OTHER

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma

Interventions

DRUG: Bevacizumab
DRUG: Erlotinib
DRUG: Imatinib

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]
[object Object]